Assess whether labeling language overclaims the evidence (e0ef7e)

Situation

An inspector asking for batch records you cannot produce this week put biosimilar analytical similarity report in front of labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / CMC and Development Pathways close is labeling language overclaims the from biosimilar analytical similarity report, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• The population in biosimilar analytical similarity report is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in biosimilar analytical similarity report is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained an inspector asking for batch records you cannot produce this week before biosimilar analytical similarity report arrived; no new CMC and Development Pathways path.
• Provenance on biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on labeling language overclaims the.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against an inspector asking for batch records you cannot produce this week and write the one fact that would move labeling language overclaims the for labeling negotiator.

Recommendation